Last reviewed · How we verify
Alimix (CISAPRIDE)
Cisapride (Alimix) is a marketed drug primarily indicated for gastroesophageal reflux disease, enhancing gastrointestinal motility through increased acetylcholine release in the enteric nervous system. Its key competitive advantage lies in its mechanism of action, which differentiates it from metoclopramide, a same-class competitor with a patent expiry in November 2038. The primary risk to Alimix is the key composition patent expiry in 2028, which could lead to generic competition and potential revenue erosion.
At a glance
| Generic name | CISAPRIDE |
|---|---|
| Drug class | High Risk QT Prolonging Agents |
| Target | 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
- Gastroesophageal reflux disease
Common side effects
Drug interactions
- High Risk QT Prolonging Agents
- Strong CYP3A4 Inhibitors
- amiodarone
- bepridil
- boceprevir
- bretylium
- bumetanide
- clarithromycin
- clomipramine
- darunavir
- delavirdine
- desipramine
Key clinical trials
- Limited Access Protocol for the Use of Oral Cisapride
- An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus (PHASE4)
- A Study of Cisapride in Premature Infants With Feeding Problems (PHASE4)
- An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options (PHASE4)
- A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alimix CI brief — competitive landscape report
- Alimix updates RSS · CI watch RSS